[Conservative treatment of peripheral arterial occlusive diseases].
The therapeutical effect and tolerance of Defluina was studied in a selective open trial of 24 patients suffering from peripheral arterial diseases in Fontaine's stage I and II. All patients were treated with Defluina, 30 drops three times a day during a period of six weeks. From the statistically significant improvement of the different control parameters it can be concluded that peripheral arterial circulation has increased considerably in the course of the Defluina treatment. The preparation was always well tolerated, no side-effects were observed.
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004087:Dihydroergotamine / Q000008:administration & dosage*; D004088:Dihydroergotoxine; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014665:Vasodilator Agents / Q000008:administration & dosage*; D015016:Yohimbine / Q000008:administration & dosage*
D004338:Drug Combinations; D014665:Vasodilator Agents; D004088:Dihydroergotoxine; D015016:Yohimbine; D004087:Dihydroergotamine
Zur konservativen Behandlung peripherer arterieller Durchblutungsstörungen.